ES2038571T1 - Procedimiento de preparacion de anticuerpos monoclonales especificos de las interleucinas 1alfa y 1beta. - Google Patents

Procedimiento de preparacion de anticuerpos monoclonales especificos de las interleucinas 1alfa y 1beta.

Info

Publication number
ES2038571T1
ES2038571T1 ES199090900216T ES90900216T ES2038571T1 ES 2038571 T1 ES2038571 T1 ES 2038571T1 ES 199090900216 T ES199090900216 T ES 199090900216T ES 90900216 T ES90900216 T ES 90900216T ES 2038571 T1 ES2038571 T1 ES 2038571T1
Authority
ES
Spain
Prior art keywords
antibodies
monoclonal antibodies
1alfa
1beta
interleukins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES199090900216T
Other languages
English (en)
Inventor
Yveline Frobert
Jacques Grassi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Publication of ES2038571T1 publication Critical patent/ES2038571T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ANTICUERPOS MONOCLONALES ANTI-INTERLEUQUINAS-1. LOS ANTICUERPOS REFERIDOS SON ANTICUERPOS MONOCLONALES ANTI-IL-1(ALFA) Y ANTI-IL-1(BETA). LA INVENCION SE REFIERE IGUALMENTE A CONJUGADOS DE ANTICUERPOS MONOCLONALES ANTI-IL-1(ALFA)-ACHE Y A CONJUGADOS DE ANTICUERPOS MONOCLONALES ANTI-IL-1(BETA)-ACHE, ASI COMO A CONJUGADOS ACHE-FRAGMENTOS DE LOS ANTICUERPOS. DICHOS ANTICUERPOS MONOCLONALES Y CONJUGADOS TIENEN NUMEROSAS APLICACIONES: ENSAYOS ENZIMO-INMUNOMETRICOS, AGENTES DE DIAGNOSTICO, AGENTES DE FUNCIONES TERAPEUTICAS.
ES199090900216T 1988-12-08 1989-12-08 Procedimiento de preparacion de anticuerpos monoclonales especificos de las interleucinas 1alfa y 1beta. Pending ES2038571T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8816165A FR2640146B1 (fr) 1988-12-08 1988-12-08 Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique

Publications (1)

Publication Number Publication Date
ES2038571T1 true ES2038571T1 (es) 1993-08-01

Family

ID=9372733

Family Applications (1)

Application Number Title Priority Date Filing Date
ES199090900216T Pending ES2038571T1 (es) 1988-12-08 1989-12-08 Procedimiento de preparacion de anticuerpos monoclonales especificos de las interleucinas 1alfa y 1beta.

Country Status (7)

Country Link
EP (1) EP0399024A1 (es)
JP (1) JPH04503600A (es)
CA (1) CA2004935A1 (es)
DE (1) DE399024T1 (es)
ES (1) ES2038571T1 (es)
FR (1) FR2640146B1 (es)
WO (1) WO1990006371A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
WO2007015128A1 (en) 2005-08-02 2007-02-08 Xbiotech Inc. DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
KR101567117B1 (ko) 2008-05-30 2015-11-06 엑스바이오테크, 인크. 인터류킨-1 알파 항체 및 그의 사용 방법
CA2737056C (en) 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR20130108305A (ko) 2010-08-23 2013-10-02 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP6456015B2 (ja) * 2013-07-19 2019-01-23 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
WO2018150265A1 (en) 2017-02-16 2018-08-23 Xbiotech, Inc. Treatment of hidradenitis suppurativa
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6291197A (ja) * 1985-10-17 1987-04-25 Dainippon Pharmaceut Co Ltd 抗ヒトインタ−ロイキン１抗体，その製法及びその使用法
ZA872784B (en) * 1986-05-01 1987-10-16 Immunex Corporation Detection of inflammation and novel antibodies therefor
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1

Also Published As

Publication number Publication date
FR2640146A1 (fr) 1990-06-15
CA2004935A1 (fr) 1990-06-08
EP0399024A1 (fr) 1990-11-28
JPH04503600A (ja) 1992-07-02
WO1990006371A1 (fr) 1990-06-14
FR2640146B1 (fr) 1993-12-24
DE399024T1 (de) 1991-04-11

Similar Documents

Publication Publication Date Title
ES2038571T1 (es) Procedimiento de preparacion de anticuerpos monoclonales especificos de las interleucinas 1alfa y 1beta.
DK0403156T3 (da) Forbedrede monoklonale antistoffer mod den humane alfa/beta-T-cellereceptor samt fremstilling og anvendelse deraf
ES2149772T3 (es) Receptores humanos pf4a y su utilizacion.
FI930580A (fi) Tri- och tetravalensiska monopecifika antigen bindande proteiner
DE3789716D1 (de) Mechanisch verstärkter Tubus für Heilzwecke.
DE68915812D1 (de) Funktionspezifische Antikörper.
ATE214943T1 (de) Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor
ES2128362T3 (es) Fragmentos de proteinas de prion.
ATE233524T1 (de) Medizinische bandage
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
DE3773416D1 (de) Fuehrungsrohr fuer medizinische instrumente.
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
DK0384331T3 (da) Bloddelingsmiddel
ES2065863T1 (es) Ensayo del virus de la hepatitis c.
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
DK0395853T3 (da) Rekombinant proteinreceptor
DE3773738D1 (de) Fuehrungsrohr fuer medizinische instrumente.
ES2115622T5 (es) Clones moleculares de hiv-1 y usos de los mismos.
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
DK355483A (da) Monoklonale antistoffer til krydsafstemning af humant vaev
YU13392A (sh) ANTITELA NA HUMANI RECEPTOR ZA IgE
DK0417003T3 (da) Anvendelse af antiprogestomimetiske forbindelser til fremme af ovulation
ES536059A0 (es) Procedimiento de ligacion de sustancias biologicamente importantes
DE69028713D1 (de) Schimäre immunoglobuline für cd4-rezeptoren
DE59105603D1 (de) Monoklonale antikörper gegen den interleukin 2-rezeptor.